research Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response
Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
research Atopic Dermatitis And Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Therapeutics for COVID-19 and Post COVID-19 Complications: An Update
New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.
research Stress-Induced Premature Senescence of Dermal Papilla Cells Compromises Hair Follicle Epithelial-Mesenchymal Interaction
Stress can cause early aging in certain skin cells, leading to problems with hair growth.
research Serum Level of Macrophage Migration Inhibitory Factor in Egyptians With Alopecia Areata and Its Relation to the Clinical Severity of the Disease
Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.
research What Is Behind the 'Swarm of Bees' in Alopecia Areata
Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.